Mechanisms, Biomarkers and Therapeutic Implications of Neuroinflammation in Alzheimer's Disease
International Journal of Developmental Neuroscience · 2026-08 · 86 (5)
DOI: 10.1002/jdn.70168 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Developmental Neuroscience, online erschienen am 06.08.2026. Verfasst von Shaunt Papelian. Beteiligte Einrichtung: Department of Cell Biology and Neuroscience, University of California, Riverside, California, USA. Hauptthemen laut MEDLINE: Alzheimer Disease, Biomarkers, Neuroinflammatory Diseases. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Demenz
Abstract (Originalsprache)
Alzheimer's disease ( AD ) represents the most prevalent neurodegenerative disorder worldwide, affecting millions of individuals and imposing substantial socioeconomic burdens. While traditional research has focused on amyloid‐β (Aβ) plaques and neurofibrillary tangles as primary pathological hallmarks, mounting evidence implicates neuroinflammation as a critical third pillar in AD pathogenesis. This review critically evaluates current understanding of neuroinflammatory mechanisms in AD , examining the complex interplay between cellular mediators, molecular pathways and environmental triggers across a temporal disease‐stage framework. We explore the dual and stage‐dependent roles of microglia and astrocytes, expand discussion of blood–brain barrier (BBB) dysfunction and peripheral immune infiltration as underappreciated pathogenic contributors, and integrate emerging evidence linking neuroinflammation specifically to tau pathology and its stereotyped propagation through the brain. Diagnostic biomarkers, including translocator protein–positron emission tomography (TSPO‐PET) and plasma glial fibrillary acidic protein (GFAP), are evaluated with explicit attention to clinical utility, technical limitations, and their relationship to established AD biomarkers. Therapeutic strategies are critically assessed with careful distinction between preclinical proof‐of‐concept data and available clinical evidence, and key translational challenges are highlighted throughout. The review emphasizes the need for stage‐appropriate intervention windows, patient stratification by neuroinflammatory endotype, and biologically rational combination strategies. Understanding neuroinflammation's temporal and spatial dynamics offers promising but as yet insufficiently realized avenues for early intervention and disease modification in AD .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cell Biology and Neuroscience, University of California, Riverside, California, USA.
ORCID-Profile: Shaunt Papelian
Zitieren
APA
Papelian, S. (2026). Mechanisms, Biomarkers and Therapeutic Implications of Neuroinflammation in Alzheimer's Disease. International Journal of Developmental Neuroscience, 86(5). https://doi.org/10.1002/jdn.70168
Vancouver
Papelian S. Mechanisms, Biomarkers and Therapeutic Implications of Neuroinflammation in Alzheimer's Disease. International Journal of Developmental Neuroscience. 2026;86(5). doi:10.1002/jdn.70168
BibTeX
@article{Papelian2026,
author = {Papelian, Shaunt},
title = {Mechanisms, Biomarkers and Therapeutic Implications of Neuroinflammation in Alzheimer's Disease},
journal = {International Journal of Developmental Neuroscience},
year = {2026},
volume = {86},
number = {5},
doi = {10.1002/jdn.70168}
}
EUVIMED